VCP-979

N/A

Report date: 2025/01/26 17:40:12
NME

Base Information

Drug NameVCP-979
Drug Alias NameMAPK inhibitor (Baker IDI Heart & Diabetes Institute/Monash University)VCP-979
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 α mitogen-activated protein kinase inhibitors
TargetsP38 α mitogen-activated protein kinase
Therapy Area/IndicationsMyocardial Reperfusion InjuryNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBaker Idi Heart And Diabetes Institute Holdings Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBaker Idi Heart And Diabetes Institute Holdings LtdMonash University
Inactive CompaniesN/A
Active IndicationsMyocardial Reperfusion InjuryNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A